Medline (NASDAQ:MDLN) Upgraded at Baird R W

Baird R W upgraded shares of Medline (NASDAQ:MDLN) to a strong-buy rating in a report released on Monday,Zacks.com reports.

Other analysts also recently issued research reports about the stock. Royal Bank Of Canada started coverage on shares of Medline in a research report on Monday. They issued an “outperform” rating and a $47.00 price objective for the company. BMO Capital Markets started coverage on shares of Medline in a research note on Monday. They issued an “outperform” rating and a $45.00 target price for the company. The Goldman Sachs Group began coverage on shares of Medline in a research note on Monday. They set a “buy” rating and a $49.00 price target on the stock. Truist Financial assumed coverage on shares of Medline in a report on Monday. They issued a “buy” rating and a $52.00 price objective on the stock. Finally, Jefferies Financial Group began coverage on Medline in a research note on Monday. They set a “buy” rating and a $50.00 target price for the company. Two investment analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and six have issued a Hold rating to the stock. According to data from MarketBeat.com, Medline currently has a consensus rating of “Moderate Buy” and an average price target of $46.70.

Medline Price Performance

MDLN stock opened at $43.41 on Monday. Medline has a 1 year low of $34.89 and a 1 year high of $45.50.

Insider Transactions at Medline

In related news, Director Andrew J. Mills bought 2,586,206 shares of the business’s stock in a transaction dated Thursday, December 18th. The shares were acquired at an average price of $29.00 per share, for a total transaction of $74,999,974.00. Following the purchase, the director owned 2,586,206 shares in the company, valued at $74,999,974. This trade represents a ∞ increase in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, major shareholder Hellman & Friedman Capital Par sold 6,088,371 shares of the stock in a transaction dated Thursday, December 18th. The stock was sold at an average price of $28.37, for a total transaction of $172,727,085.27. Following the transaction, the insider directly owned 4,806,160 shares in the company, valued at $136,350,759.20. The trade was a 55.88% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure.

Medline News Roundup

Here are the key news stories impacting Medline this week:

• Positive Sentiment: Several major brokers initiated bullish coverage or set high price targets (Truist $52, Evercore $50, BTIG $50, Goldman $49, Sanford Bernstein $49, UBS $48, RBC $47, BMO $45, Leerink/Baird strong-buy). Those reports signal upward earnings/market-share expectations and provide concrete upside targets for investors, supporting the rally. Analyst Coverage & Targets (Benzinga)
• Neutral Sentiment: Widespread coverage initiations across big banks (Deutsche Bank, Jefferies, Wells Fargo, JPMorgan, Citigroup, Barclays, Mizuho, TD Cowen, Wolfe Research, Rothschild/Redburn, BNP Paribas Exane) increase the stock’s visibility and institutional research footprint—likely to lift liquidity and investor interest over time but not an immediate fundamental change on its own. Coverage Initiations (AmericanBankingNews)
• Neutral Sentiment: Press coverage highlighting a strong market debut and “aging dividend” thematic interest has helped momentum traders and retail investors take notice; this amplifies the technical lift but is not new company-specific fundamental news. Market Debut Coverage (NAI500)
• Negative Sentiment: Not all firms are uniformly bullish—BNP Paribas and Rothschild/Redb issued “hold” ratings for now. These more cautious views could cap near-term upside if other analysts temper forecasts or if results miss elevated expectations. Hold Ratings (Zacks)

Medline Company Profile

Medline (NASDAQ: MDLN) is a healthcare products and services company that manufactures, sources and distributes a wide range of medical supplies and equipment for healthcare providers. Its product portfolio spans clinical consumables and personal protective equipment, surgical and procedural supplies, wound care and incontinence products, diagnostic and laboratory supplies, and select durable medical equipment. Medline supports care settings that include hospitals, health systems, long-term care facilities, ambulatory clinics and home health providers.

In addition to product manufacturing and distribution, Medline provides supply‑chain and logistics services designed to help healthcare customers manage inventory, reduce costs and streamline operations.